Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(11):1480–1483. doi: 10.1038/bjc.1997.581

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.

R S de Jong 1, E A Slijfer 1, D R Uges 1, N H Mulder 1, E G de Vries 1
PMCID: PMC2228182  PMID: 9400945

Abstract

Etoposide phosphate is a water-soluble prodrug of etoposide. It was expected that this prodrug could be used to overcome the solubility limitations and erratic bioavailability of oral etoposide. To investigate the possibility of prodrug conversion to etoposide within the gastrointestinal lumen, etoposide phosphate was dissolved in water and incubated with human gastric juice or human bile in vitro. Samples were collected during 150 min and analysed for etoposide concentration with high-performance liquid chromatography. Conversion of prodrug to etoposide during incubation with gastric juice was negligible. There was significant conversion during incubation with bile at pH 7-8. The percentage of prodrug converted to etoposide at pH 8 after 60 min was 78 +/- 18% (mean +/- S.D.) for a 0.1 mg ml-1 prodrug solution and 36 +/- 26% for 0.5 mg ml-1. At pH 7, after 60 min 22% of prodrug was converted to etoposide when incubated at 0.1 mg ml-1 and 10% at 0.5 mg ml-1. No conversion was found after inactivation of alkaline phosphate (AP) by overnight heating of bile at 65 degrees C or by the addition of disodium edetate to the bile. In conclusion, because of AP in bile, variable conversion of etoposide phosphate to etoposide can be expected within the intestinal lumen after oral administration. This could have important pharmacokinetic consequences.

Full text

PDF
1480

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fallingborg J., Christensen L. A., Ingeman-Nielsen M., Jacobsen B. A., Abildgaard K., Rasmussen H. H. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989 Dec;3(6):605–613. doi: 10.1111/j.1365-2036.1989.tb00254.x. [DOI] [PubMed] [Google Scholar]
  2. Hande K. R., Krozely M. G., Greco F. A., Hainsworth J. D., Johnson D. H. Bioavailability of low-dose oral etoposide. J Clin Oncol. 1993 Feb;11(2):374–377. doi: 10.1200/JCO.1993.11.2.374. [DOI] [PubMed] [Google Scholar]
  3. Harvey V. J., Slevin M. L., Joel S. P., Smythe M. M., Johnston A., Wrigley P. F. Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol. 1985 Nov;21(11):1315–1319. doi: 10.1016/0277-5379(85)90310-4. [DOI] [PubMed] [Google Scholar]
  4. Joel S. P., Clark P. I., Slevin M. L. Stability of the i.v. and oral formulations of etoposide in solution. Cancer Chemother Pharmacol. 1995;37(1-2):117–124. doi: 10.1007/BF00685638. [DOI] [PubMed] [Google Scholar]
  5. Senter P. D., Saulnier M. G., Schreiber G. J., Hirschberg D. L., Brown J. P., Hellström I., Hellström K. E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842–4846. doi: 10.1073/pnas.85.13.4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Sessa C., Zucchetti M., Cerny T., Pagani O., Cavalli F., De Fusco M., De Jong J., Gentili D., McDaniel C., Prins C. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol. 1995 Jan;13(1):200–209. doi: 10.1200/JCO.1995.13.1.200. [DOI] [PubMed] [Google Scholar]
  7. Shah J. C., Chen J. R., Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm Res. 1989 May;6(5):408–412. doi: 10.1023/a:1015935532725. [DOI] [PubMed] [Google Scholar]
  8. Shevde K., Trivedi N., Gross M. Effects of clear liquids on gastric volume and pH in healthy volunteers. Anesth Analg. 1991 Apr;72(4):528–531. doi: 10.1213/00000539-199104000-00019. [DOI] [PubMed] [Google Scholar]
  9. Slevin M. L., Joel S. P., Whomsley R., Devenport K., Harvey V. J., Osborne R. J., Wrigley P. F. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol. 1989;24(5):329–331. doi: 10.1007/BF00304768. [DOI] [PubMed] [Google Scholar]
  10. de Boer JF, van Rossum MC, van Albada MP, Nieuwenhuizen TM, Lagendijk A. Probability distribution of multiple scattered light measured in total transmission. Phys Rev Lett. 1994 Nov 7;73(19):2567–2570. doi: 10.1103/PhysRevLett.73.2567. [DOI] [PubMed] [Google Scholar]
  11. de Jong R. S., Mulder N. H., Uges D. R., Kaul S., Winograd B., Sleijfer DTh, Groen H. J., Willemse P. H., van der Graaf W. T., de Vries E. G. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer. 1997;75(11):1660–1666. doi: 10.1038/bjc.1997.282. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES